Trade Surmodics Inc - SRDX CFD

Trading Conditions

• Type: CFD
• Spread: 0.13
• Long position overnight funding adjustment: -0.02237%
• Short position overnight funding adjustment: 0.00015%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: N/A
• Open: 42.79
• 1-Year Change: -0.3%
• Day's Range: 41.92 - 42.92

SurModics Company profile

About SurModics, Inc.

Surmodics, Inc. is a provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

Financial summary

BRIEF: For the three months ended 31 December 2021, SurModics, Inc. revenues increased 3% to $23M. Net loss increased from $274K to $2.8M. Revenues reflect Medical Device segment increase of 4% to $16.9M. Higher net loss reflects Medical Device segment loss increase from $593K to $3.8M, Corporate segment loss increase of 11% to $2.8M, In Vitro Diagnostics segment income decrease of 2% to $3.2M.

Equity composition

Common Stock $.05 Par, 02/11, 45M auth., 17,488,245 issd. Insiders control 4.93%. IPO: 3/98, 2M shares @ $7.50 by John G. Kinnard & Co. 12/00, 2-for-1 stock split. All Preferred Stock converted to Common at IPO. FY'03 financials are and FY'04 Q's are being CLA. 3/04 and 3/03 Q's = 6 months.